Fig. 1From: Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trialStudy design. ODT, orally disintegrating tabletBack to article page